Alterity Therapeutics Ltd 6-K, filed Sep 8, 2026
Alterity Therapeutics Ltd (ATHE)
About this 6-K
Alterity Therapeutics Ltd filed this 6-K on September 8, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Alterity Therapeutics Limited
(Name of Registrant)
Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
|
99.1 |
Cleansing Notice Under Section 708A |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
||
|
By: |
/s/ Julian Babarczy |
|
|
Julian Babarczy |
||
|
Chairman |
||
Date: September 8, 2026
Exhibit 99.1
8 September 2026
CLEANSING NOTICE UNDER SECTION 708A(5)(E) OF THE CORPORATIONS ACT
Alterity Therapeutics Limited (ASX:ATH) (the Company) advises that it has completed the issue of 8,400,000 fully paid ordinary shares (Shares) to MST Financial Services Pty Ltd (and various sub underwriters) pursuant to the underwriting agreement announced by the Company on 31 August 2026, in respect of the Company’s ATHO class of listed options exercisable at A$0.50 each on or before 31 August 2026.
The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:
|
(a) |
the Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act; and |
|
(b) |
as at the date of this notice, the Company has complied with: |
|
(i) |
the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and |
|
(ii) |
section 674 and section 674A of the Corporations Act; and |
|
(c) |
as at the date of this notice, there is no information that is “excluded information” (as defined in section 708A(7) of the Corporations Act) which is required to be disclosed by the Company in accordance with Section 708A(8) of the Corporations Act. |
This announcement is authorised for release by the Board of Alterity Therapeutics Limited.
Yours faithfully
Abby Macnish Niven
CFO & Company Secretary
T: +61 (0)3 9349 4906
E: cfo@alteritytx.com
Alterity Therapeutics Limited ACN 080 699 065
Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
www.alteritytx.com